Women’s health startup Flo Health has raised more than $200 million in Series C funding from General Atlantic, reaching a unicorn valuation of $1 billion.
Founded in 2015, the London-based startup allows users to track and monitor their menstrual cycles and get personalized insights into their reproductive health.
Users can also join digital discussion communities to discuss health and wellness issues.
Millions of women in the United States will lose their right to abortion if Roe v. Wade is overturned in 2022. As a result, many women have deleted period-tracking apps, concerned that their health data could be shared with third-party providers, potentially affecting those seeking abortions.
In response to the ruling, Flo developed an “incognito mode” that allows users to access the app without linking their name, email address, or technical identifiers to their health data, co-founder and CEO Dmitry Gurski told Business Insider.
Gurksi said Flow’s “steady, solid growth” over the past eight years helped it raise capital, amid an overall decline in funding for femtech startups in 2022 and 2023. As of June 2024, Flow has approximately 70 million monthly active users and approximately 5 million paid subscribers.
The Series C was led by growth investor General Atlantic and helped propel Flo to a unicorn valuation, making it the first purely digital consumer women’s health app to achieve unicorn status.
With this new funding, the startup will expand its user base by customizing more features for perimenopause and menopausal people. It will also work on providing more personalized features for users, such as accurate cycle and symptom predictions.
Check out the seven-slide presentation used to secure the new funding.
